Table 2. Univariable and multivariable analyses for RFS in patients who received neoadjuvant EGFR-TKIs.
| Variable | Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Sex | 1.127 | 0.420–3.024 | 0.812 | ||||
| Age | 0.667 | 0.246–1.807 | 0.425 | ||||
| FEV1% | 0.588 | 0.161–2.153 | 0.423 | ||||
| EGFR mutation type | 1.065 | 0.429–2.645 | 0.892 | ||||
| Objective response | 0.962 | 0.379–2.443 | 0.934 | ||||
| cTNM stage | 1.545 | 0.906–2.635 | 0.110 | ||||
| Neoadjuvant therapy | 0.636 | 0.083–4.845 | 0.662 | ||||
| Surgical procedure | 1.857 | 1.043–3.306 | 0.035 | 0.827 | 0.310–2.207 | 0.704 | |
| Side | 0.781 | 0.309–1.973 | 0.601 | ||||
| Blood loss | 1.000 | 0.999–1.001 | 0.748 | ||||
| Operation time | 0.766 | 0.381–1.540 | 0.455 | ||||
| ypTNM stage | 1.393 | 1.044–1.859 | 0.024 | 2.570 | 0.964–6.850 | 0.059 | |
| pT stage | 2.460 | 1.245–4.858 | 0.010 | 0.549 | 0.172–1.751 | 0.311 | |
| pN stage | 1.526 | 0.947–2.461 | 0.083 | 0.213 | 0.044–1.024 | 0.054 | |
| VPI | 2.291 | 0.610–8.606 | 0.219 | ||||
| STAS | 2.752 | 0.330–22.972 | 0.350 | ||||
| Dissected nodal station | 1.238 | 0.805–1.905 | 0.331 | ||||
| Dissected nodal number | 1.098 | 1.000–1.204 | 0.049 | 1.080 | 0.969–1.205 | 0.166 | |
| High-risk subtype | 2.729 | 1.055–7.060 | 0.038 | 24.560 | 2.016–299.227 | 0.012 | |
| MPR | 0.184 | 0.024–1.411 | 0.103 | ||||
RFS, relapse-free survival; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; HR, hazard ratio; CI, confidence interval.